QuidelOrtho, a major player in point-of-care diagnostic testing, is introducing the QuickVue Influenza + SARS Test to its range of products. This quick test is approved under 510(k) and CLIA-waived, making it suitable for use in various professional environments like doctor’s offices, urgent care centers, emergency rooms, pharmacies, and hospital labs.
Health Technology Insights: Valvoline, Blood Cancer United & Hendrick Motorsports Unite
It can detect three types of antigens—flu A, flu B, and SARS-CoV-2—from one nasal swab and gives results in about 10 minutes. This fast detection helps doctors quickly tell the difference between flu and COVID-19, which can lead to quicker decisions and better care for patients.
The test is designed to be user-friendly, with an easy way to collect samples, a simple process, and a clear way to read the results.
Health Technology Insights: Lōvu Health Raises $8Million Series A to Transform Maternal Care
Tammi Ranalli, PhD, Senior Vice President of Molecular Diagnostics and Point of Care Business Units at QuidelOrtho, says the new test gives healthcare professionals a reliable, cost-effective, and efficient option for quickly identifying respiratory infections.
This new test adds to QuidelOrtho’s existing line of respiratory diagnostics, including the SOFIA² Flu + SARS Antigen FIA, by providing a version that can be read visually instead of needing special equipment. It is now available in the U.S. through QuidelOrtho’s usual distribution system and is not meant for home use.
Health Technology Insights: Health Catalyst Names Ben Albert President and COO
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
